Company Overview
Our Mission
Greystone Pharmaceuticals, Inc. is dedicated to bringing its patented platform of wound care technologies to the global marketplace, using them to improve quality of life and healthcare outcomes for patients who suffer from chronic wounds, and to lower healthcare costs associated with chronic wound treatment.
Dedicated to Making a Difference
For patients living with chronic wounds, every-day activities can be painful and challenging. The incidence of chronic wounds is a growing, global problem. In the United States alone, it is projected that the incidence of chronic wounds will rise significantly, with five to seven million chronic wounds estimated annually. The management and treatment of chronic wounds in the U.S. presently costs an estimated $20 billion per year.
At Greystone Pharmaceuticals, Inc., we have developed innovative new wound care technologies that can help patients with chronic and non-responding wounds lead more active, productive and pain-free lives. Our current product line includes Epi-Max® in the United States and DerMax® and MelMax® in the European Union and the Middle East. Our goal is to become a global leader in the treatment of chronic wounds and to leverage our expertise in wound treatment to develop new products and applications using our innovative Polyhydrated Ionogen (PHI) technology.
Subsidiaries
Greystone Pharmaceuticals, Inc. wholly owns a number of subsidiary companies that represent its interest in offering patients and healthcare providers solutions for hard-to-heal wounds and improvement of skin integrity. These include:
- Dermagenics U.S., Inc. (U.S. Wound Care)
- Dermagenics BV (Europe & Middle East Wound Care)
- Greystone Research Group, Inc. (Research & Development)
- Dermedics, Inc. (Cosmeceuticals)